Report written by: Andrew Rambaut1, Nick Loman2, Oliver Pybus3, Wendy Barclay4, Jeff Barrett5, Alesandro Carabelli6, Tom Connor7, Tom Peacock4, David L Robertson8, Erik Volz4, on behalf of COVID-19 Genomics Consortium UK (CoG-UK)9. University of Edinburgh University of Birmingham University of Oxford Imperial College London Wellcome Trust Sanger Institute University of Cambridge Cardiff University MRC-University of […]
Background The WHO-COM is an expert group of more than 150 scientists around the world with expertise in animal models of viral diseases. Since February 2020 the group has met weekly to discuss advances, foster collaborations, share resources and reagents and avoid duplication of effort. The WHO-COM met on 22 December 2020 to discuss current […]
Originator: CMO Messaging From: CMO Messaging Issue date: 24-Dec-2020 18:20:50 This alert has been issued to: · NHS Regional Offices · NHS Foundation Trusts (England) – Medical Director · NHS Foundation Trusts (England) – Chief Executive · NHS Trusts (England) – Medical Director · NHS Trusts (England) – Chief Executive Other contacts · Independent Healthcare […]
The new variant transmits more easily than the previous one but there is no evidence that it is more likely to cause severe disease or mortality. Main points Data from whole genome sequencing, epidemiology and modelling suggest the new variant ‘VUI – 202012/01’ (the first Variant Under Investigation in December 2020) transmits more easily than […]
GeneMedi pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) spike-HV 69-70 Deletion mutation(ΔH69/ΔV70) Taking responsibility to help accelerate the COVID-19 vaccine and therapeutic antibody discovery and development, GeneMedi had developed the pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) spike-HV 69-70 Deletion mutation(ΔH69/ΔV70), which will meet the evaluation of the efficacy of COVID19 vaccines and therapeutic antibodies. GeneMedi codon-optimized […]
GeneMedi pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) Spike-N501Y mutation Taking responsibility to help accelerate the COVID-19 vaccine and therapeutic antibody discovery and development, GeneMedi had developed the pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) spike-N501Y mutation, which will meet the evaluation of the efficacy of COVID19 vaccines and therapeutic antibodies. SARS-COV-2 (2019nCOV) variant-N501Y mutation of Spike […]
GeneMedi pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) B.1.1.7 lineage Taking responsibility to help accelerate the COVID-19 vaccine and therapeutic antibody discovery and development, GeneMedi had developed the pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) B.1.1.7 lineage, which will meet the evaluation of the efficacy of COVID19 vaccines and therapeutic antibodies. SARS-COV-2 (2019nCOV) B.1.1.7 lineage of Spike […]
Products list of Spike trimer (P2-mutant, S1/S2 cleavage site (furin cleavage sequence)-mutant, trimerization modified) SARS-CoV-2 P2-mutated Spike protein trimer variant (P2-mutant, S1/S2 cleavage site（furin cleavage sequence)-mutant, trimerization modified) The world is in midst of the COVID-19 pandemic caused by SARS-CoV-2 (2019nCoV) infection. The Spike protein (S-protein) of SARS-CoV-2 (2019nCoV) mediates receptor (ACE2) binding and cell […]
PDF Download The ongoing worldwide severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic has a tremendous influence on public health. There is an urgent need for developing accurate detection technologies for COVID-19 pandemic. Several diagnostic strategies are available to identify or rule out current infection, identify people in need of care escalation, or to test […]
High blood pressure (hypertension) is a common disorder. it may eventually cause health problems, such as heart disease. Subgroups of the patients have been identified on the basis of their responses to hormonal and biologic stimuli. These subgroups include low-renin hypertensives and nonmodulators. Aldosterone, the principal human mineralocorticoid, which control blood pressure by holding onto […]
